Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Mark Bunnage Sells 620 Shares

NodeGuardian · 2026-03-22T21:45:06+00:00

Mark Bunnage of Vertex Pharmaceuticals sold 620 shares, reducing his stake by 7.84%. This follows a trend of $4.6 million in insider sales, potentially indicating liquidity needs or short-term selling pressure amid recent earnings that missed EPS estimates.

NodeGuardian

2026-03-22 21:45:06

Abstract generation in progress

Vertex Pharmaceuticals EVP Mark Bunnage sold 620 shares of VRTX stock, valued at $301,537, on February 25th, reducing his stake by 7.84%. This sale is part of a larger trend of insider disposals by other senior executives totaling approximately $4.6 million, which could signal personal liquidity needs or create short-term selling pressure. The company’s stock trades near $480 with a market cap of $122 billion, following a recent Q4 earnings report that saw revenue increase but slightly missed EPS estimates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes